World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
107
Citations
46435
World Ranking
6199
National Ranking
3304

David S. Hong publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where David S. Hong sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 984 publications — 94th percentile

94% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

David S. Hong D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where David S. Hong sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 107 D-Index — 70th percentile

70% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

David S. Hong is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research spans multiple areas within medicine, with a strong focus on oncology and biochemistry, genetics, and molecular biology.

The scientist has contributed extensively to the fields of oncology, pulmonary and respiratory medicine, molecular biology, cancer research, and immunology. Their work covers a broad spectrum of topics related to cancer, including lung cancer treatments and mutations, colorectal cancer treatments and studies, cancer immunotherapy and biomarkers, cancer genomics and diagnostics, CAR-T cell therapy research, pancreatic and hepatic oncology research, and immunotherapy and immune responses.

David S. Hong has published a significant number of papers, with frequent contributions in the following journals:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Cancer Research
  • Regular and Young Investigator Award Abstracts
  • Clinical Cancer Research

Their recent papers illustrate a focus on targeted cancer therapies and clinical trials. Notable works include:

  • KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors, 2020, New England Journal of Medicine
  • Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials, 2020, The Lancet Oncology
  • Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours, 2020, British Journal of Cancer

David S. Hong collaborates frequently with several researchers, including:

  • Funda Meric-Bernstam
  • Sarina A. Piha-Paul
  • Siqing Fu
  • Daniel D. Karp
  • Apostolia M. Tsimberidou

Their research contributions significantly engage with advanced cancer therapies, biomarker identification, and molecular mechanisms underlying cancer progression and treatment response.

Best Publications

  • Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

    Alexander Drilon;Theodore W. Laetsch;Shivaani Kummar;Steven G. DuBois

  • The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

    Jude Canon;Karen Rex;Anne Y. Saiki;Christopher Mohr

  • KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.

    David S. Hong;Marwan G. Fakih;John H. Strickler;Jayesh Desai

  • Autophagy as a target for anticancer therapy

    Filip Janku;David J. McConkey;David S. Hong;Razelle Kurzrock

  • Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials

    David S Hong;Steven G DuBois;Shivaani Kummar;Anna F Farago

  • Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors

    Muhammad S. Beg;Andrew J. Brenner;Jasgit Sachdev;Mitesh Borad

  • Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours.

    David S. Hong;Yoon Koo Kang;Mitesh Borad;Jasgit Sachdev

  • Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer

    Razelle Kurzrock;Steven I. Sherman;Douglas W. Ball;Arlene A. Forastiere

  • Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative

    Apostolia M. Tsimberidou;Nancy G. Iskander;David S. Hong;Jennifer J. Wheler

  • Interleukin-6 and its receptor in cancer: implications for translational therapeutics

    David S. Hong;Laura S. Angelo;Razelle Kurzrock

  • Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications

    Chaitanya R. Churi;Rachna Shroff;Ying Wang;Asif Rashid

  • Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials

    Funda Meric-Bernstam;Lauren Brusco;Kenna Shaw;Chacha Horombe

  • Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)

    Scott Kopetz;Katherine A. Guthrie;Van K. Morris;Heinz Josef Lenz

  • AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer

    David Sanghyun Hong;Razelle Kurzrock;Youngsoo Kim;Richard Woessner

  • PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors

    Filip Janku;Apostolia Maria Tsimberidou;Ignacio Garrido-Laguna;Xuemei Wang

  • 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma.

    Stephen G. Swisher;Jeremy Erasmus;Mary Maish;Arlene M. Correa

  • Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?

    Chad Tang;Xiaohong Wang;Hendrick Soh;Steven Seyedin

  • Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes.

    Chad Tang;Zhongxing Liao;Daniel Gomez;Lawrence Levy

  • Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells

    Chad Tang;James W. Welsh;Patricia de Groot;Erminia Massarelli

  • Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions

    David Sanghyun Hong;Udai Banerji;Udai Banerji;Bahareh Tavana;Goldy C George

Frequent Co-Authors

Razelle Kurzrock
Razelle Kurzrock Medical College of Wisconsin
Filip Janku
Filip Janku The University of Texas MD Anderson Cancer Center
Sarina Anne Piha-Paul
Sarina Anne Piha-Paul The University of Texas MD Anderson Cancer Center
Apostolia Maria Tsimberidou
Apostolia Maria Tsimberidou The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam
Funda Meric-Bernstam The University of Texas MD Anderson Cancer Center
Kenneth R. Hess
Kenneth R. Hess The University of Texas MD Anderson Cancer Center
Scott Kopetz
Scott Kopetz The University of Texas MD Anderson Cancer Center
Rajyalakshmi Luthra
Rajyalakshmi Luthra The University of Texas MD Anderson Cancer Center
Michael J. Overman
Michael J. Overman The University of Texas MD Anderson Cancer Center
John V. Heymach
John V. Heymach The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

The medical field offers a broad range of degree options and career paths beyond traditional medical school. If you're interested in starting your healthcare career quickly, adn nursing programs provide a fast track to becoming a registered nurse, often with flexible admission criteria.

For those who prefer a non-clinical path, healthcare administration is a popular choice. A healthcare administration degree can open doors to management roles in hospitals, clinics, and other medical facilities, with many accredited programs available fully online.

Students seeking even more accessible options should consider nursing school that don't require teas. These programs eliminate common standardized test barriers, making entry smoother for aspiring nurses.

Additionally, medical billing and coding schools that accept fafsa give students a pathway into healthcare administration and records, often with financial aid options.

Each of these online degrees presents flexible and rewarding opportunities to enter and advance in the healthcare sector.

Best Scientists Citing David S. Hong

Trending Scientists

Recently Published Articles